Income Statement
MINK THERAPEUTICS, INC.
INKT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
12.49 | 10.65 | 22.92 | 30.95 | 18.61 |
|
Research & Development
|
5.76 | 6.34 | 15.49 | 23.12 | 13.97 |
|
Selling, General & Administrative
|
6.73 | 4.31 | 7.43 | 7.83 | 4.64 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-12.49 | -10.65 | -22.92 | -30.95 | -18.61 |
|
Non-Operating Income
|
- | - | - | - | - |
|
Interest Income
|
0.29 | 0.27 | - | - | - |
|
Interest Expense
|
-0.11 | -0.09 | - | - | 2.43 |
|
Other Non-Op Income / Expense
|
-0.03 | 0.33 | 0.00 | 2.70 | 0.22 |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-12.49 | -10.78 | -22.46 | -27.99 | -30.21 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-12.49 | -10.65 | -22.92 | -30.95 | -18.61 |
|
Earnings Per Share (Basic)
|
-2.93 | -2.86 | -0.65 | -0.83 | - |
|
Diluted EPS
|
-2.93 | -2.86 | -0.65 | -0.83 | - |
|
Weighted Average Shares
|
4.27 | 3.77 | 34.36 | 33.67 | - |
|
Diluted Weighted Avg Shares
|
4.27 | 3.77 | 34.36 | 33.67 | - |
|
Comprehensive Income
|
-12.58 | -10.99 | -22.60 | -27.66 | -29.32 |